Browsing Category

Features

1009 posts

CDMO Insights: What’s Trending in the Injectable Drug Market?
By

By
GPL-1s for treating Type 2 diabetes and obesity have been a key growth driver for the bio/pharma industry as well as for CDMOs of injectables, but will the entry of oral GLP-1s and related drugs put a damper on growth prospects for injectables? What is the expected market penetration?

Pharma Customer–Supplier Insights: What Constitutes Value Creation?
By

By
Delivering value beyond product and price is crucial for CDMOs and suppliers to gain a competitive edge with their bio/pharma customers, but are the buy and sell side aligned in what constitutes value? The latest DCAT Benchmarking & Research study provides key insights.

Small-Molecule CDMO Outlook: What Lies Ahead
By

By
At the mid-point in 2026, how are small-molecule CDMOs faring? Larger CDMOs are faring well while CDMOs in early-stage capabilities face some headwinds with more challenging biotech financing

Biotech IPOs: Who Is Topping the Class of 2026?
By

By
What companies are topping biotech IPOs in 2026? Parabilis Medicines with a focus on alpha-helical peptides and Kailera Therapeutics specializing in GLP-1s and related drugs for obesity are leading the way. By Patricia Van…

China: The Innovation Factor Coming Into Play
By

By
Pfizer’s $10.5-billion partnering deal with China’s Innovent Biologics is the latest deal between the bio/pharmaceutical majors and China-based innovator drug companies. Is China becoming a force in innovation?

Oncology Drug Market: The Ups and Downs 
By

By
ASCO’s Annual Meeting, held this week in Chicago, is when bio/pharma companies highlight the most promising in their cancer drug pipelines and portfolios. What is the outlook for the global oncology drug market?

Lilly Continues Biotech Acquisition Spree
By

By
Lilly has been active on the M&A front with a series of biotech acquisitions totaling up to more than $20 billion in 2026 to date  What moves is the company making?

Shoring up API Mfg & Supply in Europe
By

By
European policymakers reached a provisional agreement on the Critical Medicines Act, designed to strengthen the EU’s pharma manufacturing base. What is next?

FDA: The Changing of the Guard: What May Be Next?
By

By
Dr. Marty Makary stepped down this week as FDA Commissioner, marking the latest leadership change at the agency. What may be the policy implications for such a move?

What’s Trending: Small-Molecule Drugs
By

By
How are small-molecule drugs faring in new drug approvals by FDA and among potential blockbuster contenders? DCAT Value Chain Insights takes an inside look.